A trial to investigate reactions and responses to BCG vaccines of different strengths prepared from the Copenhagen 1331 strain.
Seven hundred and ninety-three tuberculin-negative school-children were vaccinated with BCG vaccine prepared from either the 1077 substrain, at 0-3 mg/ml moist weight, or the 1331 substrain at 0-15 and 0-3 mg/ml moist weight. Local vaccination reactions and Mantoux tuberculin conversion were measured. There were no differences between the 1077 vaccine and the lower strength 1331 vaccine. The more potent 1331 product, however, produced marginally larger vaccination lesions and a slightly increased tuberculin allergy. The small increase in size of the vaccination lesions was considered acceptable and vaccine of this type would be satisfactory for use in the United Kingdom.
D001500:BCG Vaccine / Q000009:adverse effects / Q000592:standards; D002648:Child; D002986:Clinical Trials as Topic; D006801:Humans; D006968:Hypersensitivity, Delayed; D014374:Tuberculin Test; D006113:United Kingdom
D001500:BCG Vaccine